Pharmaceutical major Cadila Healthcare Ltd and its subsidiary Zydus Pharmaceuticals (USA) Inc., on Friday, announced that they have finalised an agreement with Upsher-Smith Laboratories, Inc. to settle all outstanding patent litigation related to Qudexy® XR (topiramate) extended-release capsules.
Zydus Pharmaceuticals (USA) Inc. is a leading generic pharmaceutical company in the United States,
Under the terms of the agreement, Upsher-Smith will grant Zydus licence to market the latter’s (Zydus’) generic version of Qudexy® XR beginning on March 19, 2020, or earlier, under certain circumstances, according to a company statement here.
Other terms of the settlement were not disclosed.